Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Daratumumab”

351 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 351 results

Post-approval studies (Phase 4)Active Not RecruitingNCT07274462
What this trial is testing

DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)

Who this might be right for
Microvascular Inflammation - MVI in Kindey Transplant Recipients
University Hospital, Martin 20
Early research (Phase 1)Active Not RecruitingNCT03283917
What this trial is testing

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Who this might be right for
Newly Diagnosed Primary AmyloidosisRecurrent Primary AmyloidosisRefractory Primary Amyloidosis
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Looking for participantsNCT05907759
What this trial is testing

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Who this might be right for
Lymphoma, Primary Effusion
National Cancer Institute (NCI) 28
Post-approval studies (Phase 4)Not Yet RecruitingNCT07191379
What this trial is testing

Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Odense University Hospital 50
Testing effectiveness (Phase 2)Study completedNCT04396496
What this trial is testing

Treatment of POEMS Syndrome With Daratumumab

Who this might be right for
POEMS Syndrome
University of Arkansas 2
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05300451
What this trial is testing

Daratumumab in HLA Desensitization Prior to Transplantation

Who this might be right for
Cardiac Transplant
Barry A. Boilson 10
Large-scale testing (Phase 3)Study completedNCT03234972
What this trial is testing

Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 213
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Early research (Phase 1)Study completedNCT05243342
What this trial is testing

Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04827979
What this trial is testing

Daratumumab and Belatacept for Desensitization

Who this might be right for
Highly Sensitized Prospective Kidney Transplant Recipients
National Institute of Allergy and Infectious Diseases (NIAID) 19
Post-approval studies (Phase 4)Looking for participantsNCT05888870
What this trial is testing

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Who this might be right for
Hemophilia A With Inhibitor
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)WithdrawnNCT03841565
What this trial is testing

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell Myeloma
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Ended earlyNCT03637764
What this trial is testing

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Who this might be right for
Neoplasm
Sanofi 107
Testing effectiveness (Phase 2)Ended earlyNCT03367819
What this trial is testing

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Who this might be right for
Prostate CancerNon-small Cell Lung Cancer
Sanofi 44
Large-scale testing (Phase 3)Looking for participantsNCT06867991
What this trial is testing

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Who this might be right for
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
The First People's Hospital of Changzhou 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03734198
What this trial is testing

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Who this might be right for
Relapsed or Refractory Chronic Lymphocytic Leukemia
French Innovative Leukemia Organisation 29
Testing effectiveness (Phase 2)WithdrawnNCT04467281
What this trial is testing

PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06974786
What this trial is testing

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07110662
What this trial is testing

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Who this might be right for
Toxic Epidermal NecrolysisImmunotherapyCutaneous Adverse Drug Reactions (CADR)
Hospices Civils de Lyon 9
Very early researchStudy completedNCT03473730
What this trial is testing

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Who this might be right for
Bladder Urothelial CarcinomaClear Cell Renal Cell CarcinomaMalignant Urinary System Neoplasm+2 more
M.D. Anderson Cancer Center 17
Load More Results